Cargando…
Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials
Background: To update the efficacy and safety data of monoclonal antibodies for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and explore the differences in the effect of treatment between patients seropositive and seronegative for AQP4-IgG. Methods: PubMed, Embase, and the Cochra...
Autores principales: | Kong, Fanxin, Wang, Jianjun, Zheng, Haotao, Cai, Haobin, Hua, Jun, Li, Liling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329455/ https://www.ncbi.nlm.nih.gov/pubmed/34354581 http://dx.doi.org/10.3389/fphar.2021.652759 |
Ejemplares similares
-
Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
por: Kim, Woojun, et al.
Publicado: (2020) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014) -
Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials
por: Xu, Xintong, et al.
Publicado: (2022) -
Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023) -
Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials
por: Xue, Tao, et al.
Publicado: (2020)